Evidence map›Paper›PMID 23277241›Full record

Trial reportJournal of clinical psychopharmacology2013

Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.

Kimberly R Warren, Robert W Buchanan, Stephanie Feldman, Robert R Conley, Jared Linthicum, Mary Patricia Ball, Fang Liu, Robert P McMahon, David A Gorelick, Marilyn A Huestis and 1 more

Erratum issuedOpen access · greenAbstract readLetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Kimberly R Warren
Robert W Buchanan
Stephanie Feldman
Robert R Conley
Jared Linthicum
Mary Patricia Ball
Fang Liu
Robert P McMahon
David A Gorelick
Marilyn A Huestis
Deanna L Kelly
University of Maryland, Baltimore · US

Funding

Pharmacokinetics And Pharmacodynamics Of Smoked Drugs Of AbuseZIADA000413 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SCHEIDWEILER, KARL · 2009 to 2016
$6.0M
Assessment Of A Cannabinoid Antagonist In HumansZIADA000415 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI HUESTIS, MARILYN A · 2009 to 2013
$1.1M
The Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Weight...R34MH077839 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI BUCHANAN, ROBERT W · 2006 to 2008
$591k
Intramural NIH HHS ZIA DA000415NIMH NIH HHS R34 MH 077839NIMH NIH HHS R34 MH077839
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Schizophrenic PsychologyAdultAntipsychotic AgentsAppetite DepressantsBody Mass IndexBody WeightBrainCannabinoid Receptor AntagonistsDouble-Blind MethodDrug Inverse AgonismEatingEnergy IntakeFemaleHumansMaleMiddle AgedAntipsychotic AgentsAppetite DepressantsCannabinoid Receptor AntagonistsCNR1 protein, humanPiperidinesPyrazolesReceptor, Cannabinoid, CB1Rimonabant

Identifiers

PMID23277241
PMCPMC3836264
OpenAlexW2056567146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.